Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors

Molecular Cancer Therapeutics

Volumn 14, Issue 11, 2015, Pages 2441-2451

  Davies, Barry R ^a   Guan, Nin ^b   Logie, Armelle ^a   Crafter, Claire ^a   Hanson, Lyndsey ^a   Jacobs, Vivien ^a   James, Neil ^a   Dudley, Philippa ^a   Jacques, Kelly ^b   Ladd, Brendon ^b   D'Cruz, Celina M ^b   Zinda, Michael ^b   Lindemann, Justin ^a   Kodaira, Makoto ^c   Tamura, Kenji ^c   Jenkins, Emma L ^b  

^a ASTRAZENECA   (United Kingdom)

^b Oncology IMED Gatehouse Park   (United States)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; DOXYCYCLINE; FUSED HETEROCYCLIC RINGS; PROTEIN KINASE B; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MISSENSE MUTATION; MULTICENTER STUDY; NEOPLASMS; NUDE MOUSE; PHASE 1 CLINICAL TRIAL; PHOSPHORYLATION; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOXYCYCLINE; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MICE, NUDE; MUTATION, MISSENSE; NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84957955911     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0230     Document Type: Article

References (24)

1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
2. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumor cell growth. Nature 2006;441:424-30.
3. cBio portal for cancer genomics. Available from: http://www.cbioportal. org/public-portal/cross-cancer.do 4.
4. Flatley E, Ang D, Warrick A, Beadling C, Corless CL, Troxell ML. PIK3CAAKT pathway mutations in micropapillary breast carcinoma. Hum Pathol 2013;44:1320-7.
5. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68:6084-91.
6. TroxellML, Levine J, Beadling C,Warrick A, Dunlap J, Presnell A, et al. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol 2010;23:27-37.
7. Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2008; 27:5648-50.
8. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, et al. AKT1(E17K) in human solid tumours. Oncogene 2008;27:5648-50.
9. Cohen Y, Shalmon B, Korach J, Barshack I, Fridman E, Rechavi G. AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol Oncol 2010;116:88-91.
10. Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 2009;101:145-8.
11. Boormans JL, KorstenH, Ziel-van derMade AC, van Leenders GJ, Verhagen PC, Trapman J. E17K substitution in AKT1 in prostate cancer. Br J Cancer 2010;102:1491-4.
12. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008;7:665-9.
13. COSMIC: catalogue of somatic mutations in cancer. Available from: http://cancer.sanger.ac.uk/cosmic.
14. Yi KH, Axtmayer J,Gustin JP, Rajpurohit A, Lauring J. Functional analysis of non-hotspot AKT1mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine. Oncotarget 2013;4:29-34.
15. Carpten JD, Faber A, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44.
16. Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, et al. PIK3CA and AKT1 mutation have distinct effects on selectivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res 2013;19:5413-22.
17. Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, et al. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 2010; 29:2337-45.
18. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67.
19. Davies BR, Greenwood H, Dudley P, Crafter C, Yu D, Zhang J, et al. Preclinical pharmacology of AZD5363, an orally bioavailable inhibitor of AKT: pharmacodynamics, antitumor activity and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012; 11:873-87.
20. Meyskens FL, Thomson SP, Moon TE. Quantitation of the number of cells within tumor colonies in semisolid medium and their growth as oblate spheroids. Cancer Res 1984;44:271-7.
21. Tomayo MM, Reynolds PC. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
22. Marangoni E, Vincent-Salomen A, Auger N, Degeorges A, Assayag F, de Cremoux P. A new model of patient derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007;13:3989-98.
23. Rudolph M, Anzender T, Ocker M, Lagkadinou E, Politz O, Michels M, et al. AKT1 (E17K) mutation: coexistence with oncogenic alterations, prevalence, and correlation to clinical parameters in a large series of breast cancer patients. AACR abstract #569, AACR Annual Meeting, San Diego, 2014.
24. Landgraf KE, Pilling C, Falke JJ. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry 2008;47: 12260-9.